Study	logRR	SE(logRR)	Risk Ratio	RR	95%-CI	Weight (common)	Weight (random)
Nakai 2022	1.8450	0.5379	-+	6.33	[2.21; 18.16]	0.0%	9.7%
Rinaldi 2019	1.1119	0.4710		3.04	[1.21; 7.65]	0.0%	10.6%
Wang 2016	1.8464	0.5699	-	6.34	[2.07; 19.36]	0.0%	9.3%
Liu 2023	1.1743	0.4829	 -	3.24	[1.26; 8.34]	0.0%	10.5%
Kuo 2021	1.0396	0.4712	 -	2.83	[1.12; 7.12]	0.0%	10.6%
Ogasawara 2020	2.2659	0.9431		9.64	[1.52; 61.22]	0.0%	5.4%
Morisco 2021	1.9741	0.6742		7.20	[1.92; 26.99]	0.0%	8.0%
Ampuero 2022	0.0198	0.0100		1.02	[1.00; 1.04]	99.7%	15.7%
Kim 2024	2.5111	0.6072	Τ	12.32	[3.75; 40.50]	0.0%	8.8%
Common effect model)	1.02	[1.00; 1.05]	100.0%	-
Random effects model				3.88	[2.28; 6.59]	-	100.0%
			1 1 1 1 . 1				
Heterogeneity:1 ² =88%, τ ²	² =0.4671, <i>P</i> <	<0.01	0.1 0.5 1 2 10				
A							
A							
A Study	logRR	SE(logRR)	Risk Ratio	RR	95%-CI	Weight (common)	Weight (random)
	logRR 1.8934	SE(logRR) 0.4931	Risk Ratio	RR 6.64	95%-CI [2.53; 17.46]	Weight (common) 14.5%	Weight (random) 14.8%
Study	•	, ,	Risk Ratio			• , ,	,
Study Nakai 2022	1.8934	0.4931	Risk Ratio	6.64	[2.53; 17.46]	14.5%	14.8%
Study Nakai 2022 Pons 2020	1.8934 1.1086	0.4931 0.5526	Risk Ratio	6.64 3.03	[2.53; 17.46] [1.03; 8.95]	14.5% 11.5%	14.8% 13.5%
Study Nakai 2022 Pons 2020 Liu 2023	1.8934 1.1086 0.4292	0.4931 0.5526 0.4248	Risk Ratio	6.64 3.03 1.54	[2.53; 17.46] [1.03; 8.95] [0.67; 3.53]	14.5% 11.5% 19.5%	14.8% 13.5% 16.5%
Study Nakai 2022 Pons 2020 Liu 2023 Ogasawara 2020	1.8934 1.1086 0.4292 2.6319	0.4931 0.5526 0.4248 0.6400	Risk Ratio	6.64 3.03 1.54 - 13.90	[2.53; 17.46] [1.03; 8.95] [0.67; 3.53] [3.96; 48.73]	14.5% 11.5% 19.5% 8.6%	14.8% 13.5% 16.5% 11.7%
Study Nakai 2022 Pons 2020 Liu 2023 Ogasawara 2020 Kuo 2022	1.8934 1.1086 0.4292 2.6319 1.0396	0.4931 0.5526 0.4248 0.6400 0.4712	Risk Ratio	6.64 3.03 1.54 - 13.90 2.83	[2.53; 17.46] [1.03; 8.95] [0.67; 3.53] [3.96; 48.73] [1.12; 7.12]	14.5% 11.5% 19.5% 8.6% 15.8%	14.8% 13.5% 16.5% 11.7% 15.3%
Study Nakai 2022 Pons 2020 Liu 2023 Ogasawara 2020 Kuo 2022 Ogawa 2020	1.8934 1.1086 0.4292 2.6319 1.0396 0.4637	0.4931 0.5526 0.4248 0.6400 0.4712 0.6809	Risk Ratio	6.64 3.03 1.54 - 13.90 2.83 1.59	[2.53; 17.46] [1.03; 8.95] [0.67; 3.53] [3.96; 48.73] [1.12; 7.12] [0.42; 6.04]	14.5% 11.5% 19.5% 8.6% 15.8% 7.6%	14.8% 13.5% 16.5% 11.7% 15.3% 10.9%
Study Nakai 2022 Pons 2020 Liu 2023 Ogasawara 2020 Kuo 2022 Ogawa 2020	1.8934 1.1086 0.4292 2.6319 1.0396 0.4637	0.4931 0.5526 0.4248 0.6400 0.4712 0.6809	Risk Ratio	6.64 3.03 1.54 - 13.90 2.83 1.59	[2.53; 17.46] [1.03; 8.95] [0.67; 3.53] [3.96; 48.73] [1.12; 7.12] [0.42; 6.04]	14.5% 11.5% 19.5% 8.6% 15.8% 7.6%	14.8% 13.5% 16.5% 11.7% 15.3% 10.9%
Study Nakai 2022 Pons 2020 Liu 2023 Ogasawara 2020 Kuo 2022 Ogawa 2020 Kim 2024	1.8934 1.1086 0.4292 2.6319 1.0396 0.4637	0.4931 0.5526 0.4248 0.6400 0.4712 0.6809	Risk Ratio	6.64 3.03 1.54 - 13.90 2.83 1.59 7.59	[2.53; 17.46] [1.03; 8.95] [0.67; 3.53] [3.96; 48.73] [1.12; 7.12] [0.42; 6.04] [3.50; 16.47]	14.5% 11.5% 19.5% 8.6% 15.8% 7.6% 22.5%	14.8% 13.5% 16.5% 11.7% 15.3% 10.9%
Study Nakai 2022 Pons 2020 Liu 2023 Ogasawara 2020 Kuo 2022 Ogawa 2020 Kim 2024 Common effect model	1.8934 1.1086 0.4292 2.6319 1.0396 0.4637	0.4931 0.5526 0.4248 0.6400 0.4712 0.6809	Risk Ratio	6.64 3.03 1.54 - 13.90 2.83 1.59 7.59	[2.53; 17.46] [1.03; 8.95] [0.67; 3.53] [3.96; 48.73] [1.12; 7.12] [0.42; 6.04] [3.50; 16.47] [2.72; 5.67]	14.5% 11.5% 19.5% 8.6% 15.8% 7.6% 22.5%	14.8% 13.5% 16.5% 11.7% 15.3% 10.9% 17.3%

Supplementary Figure 3. Forest plots of studies included in the risk ratio analysis for the prediction of HCC using VCTE measured at (A) pre-treatment and (B) after SVR. HCC, hepatocellular carcinoma; VCTE, vibration-controlled transient elastography; SVR, sustained virological response.

B